SK284552B6 - Trojvrstvová tableta s riadeným uvoľňovaním účinnej zložky na orálne podávanie - Google Patents
Trojvrstvová tableta s riadeným uvoľňovaním účinnej zložky na orálne podávanie Download PDFInfo
- Publication number
- SK284552B6 SK284552B6 SK482-2000A SK4822000A SK284552B6 SK 284552 B6 SK284552 B6 SK 284552B6 SK 4822000 A SK4822000 A SK 4822000A SK 284552 B6 SK284552 B6 SK 284552B6
- Authority
- SK
- Slovakia
- Prior art keywords
- layer
- release
- pharmaceutical composition
- methyl ester
- tablet according
- Prior art date
Links
- XBBDACCLCFWBSI-ZETCQYMHSA-N melevodopa Chemical compound COC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 XBBDACCLCFWBSI-ZETCQYMHSA-N 0.000 claims abstract description 42
- 229960001794 melevodopa Drugs 0.000 claims abstract description 42
- TZFNLOMSOLWIDK-JTQLQIEISA-N carbidopa (anhydrous) Chemical compound NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 TZFNLOMSOLWIDK-JTQLQIEISA-N 0.000 claims abstract description 28
- 229960004205 carbidopa Drugs 0.000 claims abstract description 26
- 239000003814 drug Substances 0.000 claims description 31
- 239000008187 granular material Substances 0.000 claims description 15
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 11
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 11
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 11
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 claims description 10
- 238000007906 compression Methods 0.000 claims description 9
- 230000006835 compression Effects 0.000 claims description 9
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 7
- 239000001087 glyceryl triacetate Substances 0.000 claims description 5
- 235000013773 glyceryl triacetate Nutrition 0.000 claims description 5
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 5
- 229960002622 triacetin Drugs 0.000 claims description 5
- 229920000858 Cyclodextrin Polymers 0.000 claims description 4
- 208000018737 Parkinson disease Diseases 0.000 claims description 4
- 229920002472 Starch Polymers 0.000 claims description 4
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 4
- 125000005456 glyceride group Chemical class 0.000 claims description 4
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 4
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 4
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 4
- 235000019698 starch Nutrition 0.000 claims description 4
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 3
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 3
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 3
- 229920002678 cellulose Chemical class 0.000 claims description 3
- 239000001913 cellulose Chemical class 0.000 claims description 3
- 235000010980 cellulose Nutrition 0.000 claims description 3
- 229940097362 cyclodextrins Drugs 0.000 claims description 3
- 239000008107 starch Substances 0.000 claims description 3
- SQKIRAVCIRJCFS-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;2-methylprop-2-enoic acid Chemical compound CC(=C)C(O)=O.C=CC1=CC=CC=C1C=C SQKIRAVCIRJCFS-UHFFFAOYSA-N 0.000 claims description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 2
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 2
- 229920002785 Croscarmellose sodium Polymers 0.000 claims 1
- 239000004372 Polyvinyl alcohol Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000004014 plasticizer Substances 0.000 claims 1
- 238000013270 controlled release Methods 0.000 abstract description 19
- 230000008961 swelling Effects 0.000 abstract description 12
- 239000010410 layer Substances 0.000 description 169
- 239000000203 mixture Substances 0.000 description 77
- 239000008194 pharmaceutical composition Substances 0.000 description 57
- 229940079593 drug Drugs 0.000 description 27
- 239000004480 active ingredient Substances 0.000 description 24
- 230000007246 mechanism Effects 0.000 description 23
- 238000009472 formulation Methods 0.000 description 21
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 15
- 238000002360 preparation method Methods 0.000 description 14
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 13
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 13
- 229960004502 levodopa Drugs 0.000 description 13
- 239000003826 tablet Substances 0.000 description 11
- 238000004090 dissolution Methods 0.000 description 10
- 229940001089 sinemet Drugs 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- 230000036470 plasma concentration Effects 0.000 description 8
- 229920000642 polymer Polymers 0.000 description 8
- 239000000843 powder Substances 0.000 description 8
- 239000007884 disintegrant Substances 0.000 description 7
- 238000000338 in vitro Methods 0.000 description 7
- 238000001727 in vivo Methods 0.000 description 7
- 230000003628 erosive effect Effects 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 6
- 239000002356 single layer Substances 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 239000000454 talc Substances 0.000 description 6
- 229910052623 talc Inorganic materials 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- IVTMXOXVAHXCHI-YXLMWLKOSA-N (2s)-2-amino-3-(3,4-dihydroxyphenyl)propanoic acid;(2s)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1.NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 IVTMXOXVAHXCHI-YXLMWLKOSA-N 0.000 description 5
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 5
- 239000013543 active substance Substances 0.000 description 5
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 5
- 239000008101 lactose Substances 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- 230000002093 peripheral effect Effects 0.000 description 4
- 238000005303 weighing Methods 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 230000002547 anomalous effect Effects 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 229960003638 dopamine Drugs 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 239000007942 layered tablet Substances 0.000 description 3
- WFGNJLMSYIJWII-FJXQXJEOSA-N methyl (2s)-2-amino-3-(3,4-dihydroxyphenyl)propanoate;hydrochloride Chemical compound Cl.COC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WFGNJLMSYIJWII-FJXQXJEOSA-N 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
- 229920003072 Plasdone™ povidone Polymers 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 2
- 239000008116 calcium stearate Substances 0.000 description 2
- 235000013539 calcium stearate Nutrition 0.000 description 2
- 229960004868 carbidopa anhydrous Drugs 0.000 description 2
- 229940105329 carboxymethylcellulose Drugs 0.000 description 2
- 238000007922 dissolution test Methods 0.000 description 2
- FETSQPAGYOVAQU-UHFFFAOYSA-N glyceryl palmitostearate Chemical compound OCC(O)CO.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O FETSQPAGYOVAQU-UHFFFAOYSA-N 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 229940099427 potassium bisulfite Drugs 0.000 description 2
- 235000010259 potassium hydrogen sulphite Nutrition 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 102220487426 Actin-related protein 2/3 complex subunit 3_K15M_mutation Human genes 0.000 description 1
- 229920003084 Avicel® PH-102 Polymers 0.000 description 1
- 206010008531 Chills Diseases 0.000 description 1
- 240000008415 Lactuca sativa Species 0.000 description 1
- 229920003091 Methocel™ Polymers 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000000035 biogenic effect Effects 0.000 description 1
- 230000002051 biphasic effect Effects 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- -1 blue Chemical compound 0.000 description 1
- 229920003123 carboxymethyl cellulose sodium Polymers 0.000 description 1
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000001427 coherent effect Effects 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 238000013267 controlled drug release Methods 0.000 description 1
- 239000004148 curcumin Substances 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012738 dissolution medium Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 239000004179 indigotine Substances 0.000 description 1
- 229940080383 levodopa 200 mg Drugs 0.000 description 1
- 229940080394 levodopa 250 mg Drugs 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229920005597 polymer membrane Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- DJEHXEMURTVAOE-UHFFFAOYSA-M potassium bisulfite Chemical compound [K+].OS([O-])=O DJEHXEMURTVAOE-UHFFFAOYSA-M 0.000 description 1
- 238000011867 re-evaluation Methods 0.000 description 1
- 235000012045 salad Nutrition 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000008279 sol Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Neurosurgery (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT97MI002254A IT1295271B1 (it) | 1997-10-03 | 1997-10-03 | Monolita contenente uno o piu'farmaci costituito da tre strati a meccanismo di rilascio differenziato |
| PCT/EP1998/006228 WO1999017745A1 (en) | 1997-10-03 | 1998-10-01 | Monolithic system containing one or more drugs, consisting of three layers with different release mechanisms |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| SK4822000A3 SK4822000A3 (en) | 2000-09-12 |
| SK284552B6 true SK284552B6 (sk) | 2005-06-02 |
Family
ID=11377984
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SK482-2000A SK284552B6 (sk) | 1997-10-03 | 1998-10-01 | Trojvrstvová tableta s riadeným uvoľňovaním účinnej zložky na orálne podávanie |
Country Status (14)
| Country | Link |
|---|---|
| EP (1) | EP1019029B1 (cs) |
| AR (1) | AR043070A1 (cs) |
| AT (1) | ATE248590T1 (cs) |
| AU (1) | AU9629198A (cs) |
| BR (1) | BR9815248A (cs) |
| CZ (1) | CZ298851B6 (cs) |
| DE (1) | DE69817848T2 (cs) |
| ES (1) | ES2205558T3 (cs) |
| HU (1) | HU225692B1 (cs) |
| IT (1) | IT1295271B1 (cs) |
| NO (1) | NO20001709L (cs) |
| SK (1) | SK284552B6 (cs) |
| WO (1) | WO1999017745A1 (cs) |
| ZA (1) | ZA989010B (cs) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002340470A1 (en) | 2001-11-13 | 2003-05-26 | Teva Pharmaceutical Industries, Ltd. | L-dopa ethyl ester salts and uses thereof |
| US20030224045A1 (en) * | 2002-05-29 | 2003-12-04 | Chien-Hsuan Han | Combination immediate release sustained release levodopa/carbidopa dosage forms |
| US7094427B2 (en) | 2002-05-29 | 2006-08-22 | Impax Laboratories, Inc. | Combination immediate release controlled release levodopa/carbidopa dosage forms |
| EP1901720A2 (en) * | 2005-06-23 | 2008-03-26 | Spherics, Inc. | Improved dosage forms for movement disorder treatment |
| EP1970055B1 (en) * | 2005-12-29 | 2010-11-24 | Osmotica Kereskedelmi És Szolgáltató Kft | Multi-layered tablet with triple release combination |
| WO2010019915A1 (en) | 2008-08-15 | 2010-02-18 | Depomed Inc. | Gastric retentive pharmaceutical compositions for treatment and prevention of cns disorders |
| EP2555756B1 (en) * | 2010-04-07 | 2018-08-22 | Lupin Limited | Controlled release pharmaceutical compositions of tapentadol |
| EP2508174A1 (en) | 2011-04-06 | 2012-10-10 | Ljiljana Sovic Brkicic | Pharmaceutical composition |
| US20130143867A1 (en) | 2011-12-02 | 2013-06-06 | Sychroneuron Inc. | Acamprosate formulations, methods of using the same, and combinations comprising the same |
| ITMI20121263A1 (it) * | 2012-07-19 | 2014-01-20 | Recordati Ind Chimica E Farma Ceutica S P A | Forma farmaceutica multistrato |
| EP3878445A3 (en) | 2013-06-05 | 2021-10-27 | Synchroneuron Inc. | Acamprosate formulations, methods of using the same, and combinations comprising the same |
| EP3782614A1 (en) | 2013-10-07 | 2021-02-24 | Impax Laboratories, LLC | Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof |
| US10987313B2 (en) | 2013-10-07 | 2021-04-27 | Impax Laboratories, Llc | Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof |
| GB201506755D0 (en) | 2015-04-21 | 2015-06-03 | Reckitt Benckiser Llc | Novel pharmaceutical formulation |
| US9808478B2 (en) * | 2015-04-17 | 2017-11-07 | Steven Loyd | Control release of fat soluble antioxidants from an oral formulation and method |
| CA3001337C (en) | 2015-10-09 | 2023-12-12 | Reckitt Benckiser Llc | Pharmaceutical formulation |
| EP4267113A4 (en) | 2020-12-22 | 2025-02-12 | Amneal Pharmaceuticals LLC | LEVODOPA DOSING SCHEME |
| US11986449B2 (en) | 2020-12-22 | 2024-05-21 | Amneal Pharmaceuticals Llc | Levodopa dosing regimen |
| CN117599009A (zh) * | 2023-11-10 | 2024-02-27 | 长沙晶易医药科技股份有限公司 | 一种卡左双多巴三层片及其制备方法 |
| CN118831063A (zh) * | 2024-07-18 | 2024-10-25 | 泰州越洋医药开发有限公司 | 一种三层片制剂及其制备方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1255522B (it) * | 1992-09-24 | 1995-11-09 | Ubaldo Conte | Compressa per impiego terapeutico atta a cedere una o piu' sostanze attive con differenti velocita' |
| IT1256393B (it) * | 1992-11-17 | 1995-12-04 | Inverni Della Beffa Spa | Forme matriciali multistrato per il rilascio controllato di principi attivi |
| IT1264696B1 (it) * | 1993-07-09 | 1996-10-04 | Applied Pharma Res | Forme farmaceutiche destinate alla somministrazione orale in grado di rilasciare sostanze attive a velocita' controllata e differenziata |
| IT1282576B1 (it) * | 1996-02-06 | 1998-03-31 | Jagotec Ag | Compressa farmaceutica atta a cedere la sostanza attiva in tempi successivi e predeterminabili |
-
1997
- 1997-10-03 IT IT97MI002254A patent/IT1295271B1/it active IP Right Grant
-
1998
- 1998-10-01 SK SK482-2000A patent/SK284552B6/sk unknown
- 1998-10-01 BR BR9815248-3A patent/BR9815248A/pt not_active Application Discontinuation
- 1998-10-01 WO PCT/EP1998/006228 patent/WO1999017745A1/en active IP Right Grant
- 1998-10-01 AT AT98950099T patent/ATE248590T1/de not_active IP Right Cessation
- 1998-10-01 AU AU96291/98A patent/AU9629198A/en not_active Abandoned
- 1998-10-01 DE DE69817848T patent/DE69817848T2/de not_active Expired - Lifetime
- 1998-10-01 EP EP98950099A patent/EP1019029B1/en not_active Expired - Lifetime
- 1998-10-01 HU HU0004015A patent/HU225692B1/hu not_active IP Right Cessation
- 1998-10-01 ES ES98950099T patent/ES2205558T3/es not_active Expired - Lifetime
- 1998-10-01 CZ CZ20001200A patent/CZ298851B6/cs not_active IP Right Cessation
- 1998-10-02 ZA ZA989010A patent/ZA989010B/xx unknown
- 1998-10-02 AR ARP980104937A patent/AR043070A1/es not_active Application Discontinuation
-
2000
- 2000-04-03 NO NO20001709A patent/NO20001709L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CZ298851B6 (cs) | 2008-02-27 |
| ZA989010B (en) | 1999-04-12 |
| EP1019029A1 (en) | 2000-07-19 |
| HUP0004015A2 (hu) | 2001-08-28 |
| EP1019029B1 (en) | 2003-09-03 |
| ATE248590T1 (de) | 2003-09-15 |
| WO1999017745A1 (en) | 1999-04-15 |
| SK4822000A3 (en) | 2000-09-12 |
| DE69817848D1 (de) | 2003-10-09 |
| CZ20001200A3 (cs) | 2000-09-13 |
| IT1295271B1 (it) | 1999-05-04 |
| HU225692B1 (en) | 2007-06-28 |
| AU9629198A (en) | 1999-04-27 |
| NO20001709L (no) | 2000-06-05 |
| BR9815248A (pt) | 2000-11-21 |
| HUP0004015A3 (en) | 2006-06-28 |
| AR043070A1 (es) | 2005-07-20 |
| DE69817848T2 (de) | 2005-04-07 |
| ITMI972254A1 (it) | 1999-04-03 |
| ES2205558T3 (es) | 2004-05-01 |
| NO20001709D0 (no) | 2000-04-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SK284552B6 (sk) | Trojvrstvová tableta s riadeným uvoľňovaním účinnej zložky na orálne podávanie | |
| RU2385712C2 (ru) | Рецептура с контролируемым высвобождением | |
| JP4758064B2 (ja) | 有効物質を徐放する３−（３−ジメチルアミノ−１−エチル−２−メチル−プロピル）フェノール含有医薬 | |
| JP5622773B2 (ja) | テトラサイクリンの１日１回製剤 | |
| RU2616516C2 (ru) | Фармацевтическая композиция, содержащая олмесартана медоксомил и розувастатин или его соль | |
| US7741374B1 (en) | Methods of use of fenofibric acid | |
| KR20210016416A (ko) | 글루코키나제 활성화제 및 dpp-iv 억제제를 포함하는 약제학적 병용물, 조성물 및 병용 제제, 및 이의 제조 방법 및 용도 | |
| US20060127478A1 (en) | Oral dosage formulation | |
| US20090124702A1 (en) | Pharmaceutical Compositions of Metformin | |
| WO2009034541A9 (en) | Controlled release pharmaceutical dosage forms of trimetazidine | |
| HK87893A (en) | Orally sustained-release acetaminophen formulation and process to obtain it | |
| SK30396A3 (en) | Beads, method for producing them and a pharmaceutical preparation containing the same | |
| ZA200703810B (en) | Dosage form time-lagged of drugs for the therapy of insomnia | |
| KR20090091085A (ko) | 방출성이 제어된 약제학적 제제 | |
| EP2533767A1 (en) | Pharmaceutical compositions comprising a combination of metformin and sitagliptin | |
| NZ281236A (en) | Tablet (composition) comprising paracetamol (aceta-minophen) and domperidone (5-chloro-1-[1-[3-(2,3-dihydro-2-oxo-1H-benzimidazol -1-yl) propyl]-4-piperidinyl]-1,3-dihydra-2H-benzimidazol-2-one) | |
| JP2005508901A (ja) | 活性成分を徐放する剤形 | |
| WO2021129735A1 (zh) | 一种固体制剂及其制备方法和用途 | |
| CN115192572B (zh) | 布立西坦药剂、其制备方法和应用 | |
| EP2874610B1 (en) | Multilayered pharmaceutical formulation | |
| AU2014295098B2 (en) | Anti-tuberculosis stable pharmaceutical composition in a form of a coated tablet comprising granules of isoniazid and granules of rifapentine and its process of preparation | |
| EA030466B1 (ru) | Фармацевтическая композиция, обладающая улучшенной стабильностью | |
| KR20090091075A (ko) | 심혈관계 질환 치료용 약제학적 제제 | |
| JPH08333259A (ja) | スクラルファート含有製剤組成物 | |
| KR20160105662A (ko) | 에페리손과 펠루비프로펜을 함유하는 약제학적 조성물 |